ZIOPHARM Oncology Inc. Daily Stock Analysis

Daily Stock Analysis, ZIOP, ZIOPHARM Oncology Inc, priceseries

ZIOPHARM Oncology Inc. Daily Stock Analysis
Stock Information
Open
0.87
Close
0.83
High
0.90
Low
0.79
Previous Close
0.87
Daily Price Gain
-0.04
YTD High
1.18
YTD High Date
Jan 4, 2022
YTD Low
0.77
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.34
YTD Gain
-29.47%
52 Week High
5.24
52 Week High Date
Mar 11, 2021
52 Week Low
0.77
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-3.24
52 Week Gain
-79.72%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
5.78
Jul 6. 2017
6.17
11 Trading Days
6.77%
Link
LONG
Nov 13. 2018
2.70
Dec 4. 2018
3.16
14 Trading Days
17.15%
Link
LONG
Feb 11. 2019
2.44
Mar 4. 2019
2.77
14 Trading Days
13.63%
Link
LONG
Mar 11. 2019
3.16
Mar 25. 2019
3.73
10 Trading Days
17.90%
Link
LONG
Jun 11. 2019
4.43
Jun 24. 2019
5.51
9 Trading Days
24.46%
Link
LONG
Nov 21. 2019
4.59
Dec 3. 2019
4.84
7 Trading Days
5.46%
Link
LONG
Jun 18. 2020
3.29
Jun 19. 2020
3.46
1 Trading Days
5.32%
Link
LONG
Nov 9. 2020
2.47
Dec 2. 2020
2.81
16 Trading Days
13.56%
Link
LONG
Jan 4. 2021
2.82
Feb 12. 2021
4.86
28 Trading Days
72.21%
Link
Company Information
Stock Symbol
ZIOP
Exchange
NasdaqCM
Company URL
http://www.ziopharm.com
Company Phone
617-259-1970
CEO
Laurence James Neil Cooper
Headquarters
Massachusetts
Business Address
ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON, MA 02129
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001107421
About

ZIOPHARM Oncology, Inc. is a biopharmaceutical company currently in developmental stage that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies. It is focused on two clinical stage product candidates: Ad-RTS-IL-12 + veledimex and DC-RTS-IL-12 + veledimex. Ziopharm Oncology was founded on September 9, 2003 and is headquartered in Boston, MA.

Description

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon's synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading